Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L-leucine in Major Depressive Disorder
NCT03079297Phase 2Terminated
- Sponsor
- UT Southwestern Medical Center
- Start
- Mar 2017
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing L-leucine First with Placebo First (2 arms). Primary endpoint: Change in Quick Inventory of Depressive Symptomatology-Self Report From Baseline at 14 days. Started Mar 2017; status: terminated.
02
Drugs
l-leucine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03079297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079297.